

# COMMISSION MEETING

# January 16, 2025

MassGIC

Þ

**in** Group Insurance Commission

MA Group Insurance Commission

Public Notice: G.L. C-30A, Sec. 20, January, 2025

# Agenda



>	I. Minutes, December 19, 2024 (VOTE) Valerie Sullivan, Chair Andrew Stern, General Counsel	8:30-8:35
>	<b>II. Executive Director's Report (INFORM)</b> Matthew Veno, Executive Director Members of Senior Staff	8:35-8:45
>	III. FY2024 Stewardship Meeting Summary (INFORM) Cameron McBean, Director of Vendor Management	8:45 -9:00
>	<b>IV. FY2026 Plan Design (INFORM)</b> Cameron McBean, Director of Vendor Management Matthew Veno, Executive Director	9:00-10:00
>	<b>V. Other Business/Adjournment</b> Valerie Sullivan, Chair Matthew Veno, Executive Director	10:00-10:05





#### **APPROVAL OF MINUTES (VOTE)**

Valerie Sullivan Chair & Andrew Stern General Counsel



# Motion

#### That the Commission hereby approves the minutes of its meeting held on <u>December 19, 2024</u> as presented

Valerie Sullivan, Chair
Bobbi Kaplan, Vice-Chair
Dana Sullivan (A&F Designee)
Rebecca Butler (Designee for DOI)
Elizabeth Chabot
Edward Tobey Choate
Tamara Davis
Jane Edmonds

Joseph Gentile
Gerzino Guirand
Patricia Jennings
Eileen P. McAnneny
Melissa Murphy-Rodrigues
Jason Silva
Anna Sinaiko
Timothy D. Sullivan
Catherine West




# П

#### **EXECUTIVE DIRECTOR'S REPORT (INFORM)**

Matthew Veno Executive Director & Members of Senior Staff




#### **Projected Fiscal Year 2025 Calendar**





# **2025 Public Information Sessions**

# Register\* today at <u>Mass.gov/GIC</u>



\*Please register for only one session. All sessions contain the same information.





FY2024 Stewardship Meeting Summary (Inform)

**Cameron McBean**, Director of Vendor Management



# **FY2024 Stewardship Summary**

#### There was high variation in health plan fiscal performance.

- HNE had highest Allowed PMPM (Per Member Per Month) trend at 12.6%
- **Point32** had PMPM trend of **9.5%** (first year of HPHC-only for commercial plans)
- MGB 4%
- Wellpoint 2.9%

#### Pharmacy trends were also mixed

- CVS Caremark had FY24 trend (compared to Express Scripts in FY23) of 13.4%
- CVS **Silverscript** had overall trend (net of rebates) of **-4.5%** in sixmonth reporting period (calendar-year based)



# **FY2024 Stewardship Summary**

#### **Observations**:

- **1. HNE** had unusually high trend (historically had lower trend than other carriers)
  - Trend driven by higher acuity for inpatient and outpatient, and increase in HCC's (High-Cost Claimants over \$100K)
- 2. Point32 trend also driven by increases to Inpatient, Behavioral Health, and HCC's, despite decrease in membership
- **3. MGB** noted that it saw an increase in membership, including higher risk scores among new members
  - This increase coincided with MGBHP's transition from a regional network plan to a broad network plan and the sunsetting of Tufts commercial plans.
- **4. Prescription plan** trends illustrate the impact of GLP-1's (covered under Commercial/Caremark plan for all indications, while restricted to specific conditions under Medicare)







FY2026 Plan Design (Inform)

**Cameron McBean**, Director of Vendor Management

Matthew Veno, Executive Director



# FY26 Plan Design

#### **Proposed plan design changes include:**

- Incorporate Hinge Health app (for musculoskeletal conditions) into coverage via partnership with CVS.
- Harmonize and enhance fertility benefits across plans (minimal financial impact)
  - Cover IUI without demonstrated infertility
  - IVF & Reciprocal IVF
  - Cryopreservation
- Remove Nutritional Counseling limits (recommended for mental health parity)

# GIC

# FY26 Plan Design

#### **Legislative Mandates:**

In December 2024, the legislature passed An Act Relative to Pharmaceutical Access, Costs and Transparency ("PACT Act"), which will have impacts on the GIC:

- Requires enhanced coverage for diabetes, asthma, and two most prevalent heart conditions.
  - Includes one generic (insulin for diabetes) to be covered with no (\$0) member cost-sharing, and that there be one brand name that costs no more than \$25/month.
- Carriers must implement a continuity of care program of 30day coverage for new members who currently use a medication not otherwise available (excluded from formulary).



# FY26 Plan Design

#### **Other Legislative Mandates:**

- FY25 Budget increased Basic Life/AD&D benefit to \$10K and expanded fertility coverage
- HB4918 mandates coverage of breast MRI and 3D mammography for screenings
- HB4999 coverage for human donor milk and postpartum depression screenings and home visiting services (e.g., midwives)
- HB5143 changes to pain management mandates, including removing utilization controls like step therapy for non-opioid pain medications, coverage for opioid agonists without cost share, and coverage for licensed recovery coaches
- SB2970 mandates coverage for ABA, speech, and occupational/physical therapies for those with Down Syndrome



# **FY26 PLAN DESIGN CONSIDERATIONS**

Prescription Drugs & Provider Prices



# FY26 Plan Design Considerations Regarding Prescription Drugs

- Exclude coverage of GLP-1s (not recommended)
- Shift costs to members via increased cost sharing (not recommended)

#### **Other Potential Approaches for Future Discussion**

- Secure more favorable pricing via direct negotiations
- Implement access criteria that are more stringent than FDA approval, which other states have adopted (i.e. participation in a robust weight management program, digital therapeutics)
- Place GLP-1s in a higher copay tier
- Evaluate coverage for conditions newly approved by the FDA



# FY26 Plan Design

# **Considerations Regarding Provider Prices**

- Expand outpatient site-of-service copay differentials to other services (not recommended at this time)
- Shift costs to members via increased cost sharing (not recommended)

#### Other Potential Solutions for Future Discussion (FY27 and Beyond)

- Focus on carriers with higher performance, and a demonstrated ability to provide high value to the GIC
- Broadly eliminate, or sharply constrain, access to high-cost provider systems, via changes in product types in the GIC's portfolio
- Replace or reshape the GIC's reliance on carriers to negotiate provider rates, and directly or indirectly intervene to ensure fair, sustainable unit prices





#### **OTHER BUSINESS / ADJOURNMENT**

**Valerie Sullivan**, Chair & Matthew Veno, Executive Director

## 2025 Group Insurance Commission Meetings & Schedule



Unless otherwise announced in the public notice, all meetings take place from 8:30 am - 10:30 am on the 3<sup>rd</sup> Thursday of the month. Meeting notices and materials including the agenda and presentation are available at **mass.gov/gic** under Upcoming Events prior to the meeting and under Recent Events after the meeting.

#### **Please note:**

> Until further notice, Commissioners will attend meetings remotely via a video-conferencing platform provided by GIC.

Anyone with Internet access can view the livestream via the MA Group Insurance Commission channel on YouTube. The meeting is recorded, so it can be replayed at any time.

Note: Topics and meeting dates are subject to change



#### Appendix

#### **Commission Members**

#### **GIC Leadership Team**

#### **GIC** Goals

#### **GIC Contact Channels**

#### **Commission Members**






Valerie Sullivan, Public Member, Chair



Michael Caljouw, Commissioner of Insurance







Matthew Gorzkowicz, Secretary of Administration & Finance



Elizabeth Chabot, NAGE



Edward Tobey Choate, Public Member



Tamara P. Davis, Public Member



Jane Edmonds, Retiree Member



Joseph Gentile, Public Safety Member







Patricia Jennings, Public Member



Eileen P. McAnneny, Public Member



Melissa Murphy-Rodrigues, Mass Municipal Association



Jason Silva, Mass Municipal Association



Anna Sinaiko, Health Economist



Timothy D. Sullivan, Massachusetts Teachers Association



Catherine West, Public Member

# GIC

#### **GIC Leadership Team**

Matthew A. Veno, Executive Director

Erika Scibelli, Deputy Executive Director

Emily Williams, Chief of Staff

James Rust, Chief Financial Officer

Paul Murphy, Director of Operations

Andrew Stern, General Counsel

Stephanie Sutliff , Chief Information Officer

Brock Veidenheimer, Director of Human Resources



## **GIC Goals**

1	Provide access to high quality, affordable benefit options for employees, retirees and dependents
2	Limit the financial liability to the state and others (of fulfilling benefit obligations) to sustainable growth rates
3	Use the GIC's leverage to innovate and otherwise favorably influence the Massachusetts healthcare market
Л	Evolve business and operational environment of the GIC to better

meet business demands and security standards

#### **Contact GIC for Enrollment and Eligibility**



Online Contact	mass.gov/forms/contact-the-gic		Any time. Specify your preferred method of response from GIC (email, phone, mail)	
Email	gicpublicinfo@mass.gov			
Telephone	(617) 727-2310, M-F from 8:45 AM to 5:00 PM			
Office location	1 Ashburton Place, Suite 1413, Boston, MA, Not open for walk-in service			
Correspondence & Paper Forms	P.O. Box 556 Randolph, MA 02368	Allow for processing time. Priority given to requests to retain or access benefits		



#### **Contact Your Health Carrier for Product and Coverage Questions**

Finding a Provider

- Accessing tiered doctor and hospital lists
- Determining which programs are available, like telehealth or fitness
- Understanding coverage

Health Insurance Carrier	Telephone	Website
Mass General Brigham Health Plan	(866) 567-9175	massgeneralbrighamhealthplan.com/gic-members
Harvard Pilgrim Health Care	(844) 442-7324	point32health.org/gic
Health New England	(800) 842-4464	hne.com/gic
Tufts Health Plan (Medicare Only)	(855) 852-1016	Tuftshealthplan.com/gic
Wellpoint Non-Medicare Plans Medicare Plans	(833) 663-4176 (800) 442-9300	wellpoint.com/mass



Ð

# Appendix



#### Why are we here today?

- Based on the current medical and pharmacy carriers and plan design offerings, preliminary Fiscal Year 2026 (FY26) full cost premiums were developed for each of the GIC's products (Non-Medicare and Medicare)
- The purpose of this discussion is to present FY26 Medical and Pharmacy preliminary pricing projections prior to incorporating strategic plan design changes
- A premium reflects the total sum of money that the product is expected to cost in claims and fees (for medical and pharmacy), including the Commonwealth, municipalities and member portion; typically displayed as a monthly amount

#### What are premiums?

- Out-of-pocket costs at point of service are not included in premiums (e.g., office visit copays)
- Premiums reflect the full cost members only pay a portion of the full cost premium

#### How were the premiums developed?

- Self-insured (i.e., ASO): WTW actuaries calculate FY26 premiums utilizing claims data, member data, and trend assumptions developed by the carriers; the individual and family premiums reflect the claims experience and demographics for each product offered (applies to Non-Medicare and Medicare Supplement plans for the GIC)
- Fully-insured: The carriers develop and determine the fully insured FY26 premiums for the GIC (applies to Medicare Advantage medical portion only)



Unique market dynamics are influencing health care costs, causing a significant short-term increase and uncertainty for long-term impact

General Inflation	Utilization and Service Mix	GLP-1 Drugs	Expanded Medicare Pharmacy Benefit
----------------------	-----------------------------------	-------------	---------------------------------------------

Context: Federal Employee Benefit Plan (FEBP) rate increases average 11.2% for calendar year 2025<sup>1</sup>

Applicable to Commercial + Medicare



Applicable to Medicare only

<sup>1</sup> Friedman, D Federal News Network September 2024



#### **General Inflation**


While recent reports indicate inflation rates are somewhat stabilizing, CPI is still higher now than before the pandemic

#### Incremental Health Care Inflation

Healthcare trend continues to outpace CPI, driven by contentious contract renegotiations between carriers and providers, industry consolidation, and continued clinical labor shortages, among other factors

# Expectations on organizations' healthcare costs for 2024

Source: WTW 2024 Best Practices in Healthcare Survey





#### **Utilization and Service Mix**

As more members use high-cost medical services and drugs, costs increase. The below trends were noted in the recent stewardship meetings and are common across the market.

#### **Inpatient Services**

Increased utilization of inpatient services and higher unit costs, shift in service mix to higher acuity surgeries

#### **Outpatient Services**

Higher unit cost of outpatient surgeries and tests/screening, driven by musculoskeletal and cardiovascular care

#### **GLP-1** Drugs

Sharp increase in utilization of these very high-cost drugs

#### **Medical Pharmacy**

Increased use of high-cost injectable drugs to treat autoimmune diseases like MS and Crohn's/Ulcerative Colitis, and infusion drugs to treat cancer


# Substance Use Disorder Services

Increased utilization of SUD services and higher unit costs, particularly for alcohol dependence




#### GLP-1 Drugs

GIC GLP-1 utilization and cost has grown significantly for both diabetes and weight loss. This growth is expected to continue; the cost and increased utilization of these drugs make up a significant portion of projected trend.



**Expected FY26 Budget Increase** 





Source: WTW 2024 Best Practices in Healthcare Survey.

#### **Expected FY26 Budget Increase**



#### **GLP-1** Drugs

GLP-1 medications have numerous benefits and clinical value. These drugs can prevent illness and deaths but are unlikely to lead to lower medical costs.


Diabetes	Obesity	
<ul> <li>Well-proven benefits</li> <li>Decreased progression to renal failure</li> <li>Decreased major adverse cardiovascular events</li> <li>Decreased fatty liver disease</li> <li>Decreased all cause mortality among those with kidney disease and diabetes</li> </ul>	<ul> <li>Well-proven benefits</li> <li>Decreased progression to diabetes</li> <li>Decreased major adverse cardiovascular events (MACE) and all cause mortality among those with history of cardiovascular events</li> <li>Sleep apnea</li> </ul>	
Potential GLP-1 benefits		
<ul> <li>Decreased compulsive behavior (addiction, gambling)</li> <li>Decreased obesity-related cancer (breast, colon, endometrial)</li> <li>Decrease in diagnosis of Alzheimer's dementia</li> <li>Improved mental health</li> </ul>		
References: Renal Failure, Fatty liver disease, MACE, MACE, Compulsive, Cancer, Mental Health, Diabetes, Sleep Apnea, Mortality,		

Alzheimer's Expected FY26 Budget Increase



# **Preliminary FY26 Budget Increase**

- "Preliminary" = Current plan options, programs, plan design, funding mechanism; no anticipated migration or material changes in member behavior
- 10.5% projected aggregate increase prior to plan changes and final claim adjustments



#### **Next Steps:**

- Finalize medical and pharmacy trend assumptions provided by vendor partners
- Evaluate and vote on plan design changes, including cost impacts
- Adjust the budget rates increase accordingly and develop premium rates by plan